Keywords
Last Name

Gary B. Kaplan, MD

TitleProfessor
InstitutionBoston University School of Medicine
DepartmentPsychiatry
DivisionGeneral Psychiatry
Address150 S Huntington Ave
Jamaica Plain MA 02130
Phone(774) 826-2486
Other Positions
TitleProfessor
InstitutionBoston University School of Medicine
DepartmentPharmacology & Experimental Therapeutics

InstitutionVA Boston Healthcare System

 Awards and Honors

Start-EndDescription
2016VA Boston Healthcare System: Healthcare for Homeless Veterans Appreciation Award
2013VA Boston Healthcare System: Special Contribution Award
2008-2013Marquis: Who’s Who in America
2008-2009VA Boston Healthcare System: Special Contribution Award
2007-2016Best Doctors in America
2007-2017American Psychiatric Association : Distinguished Fellow
2005Veterans Affairs Medical Center- Providence: Director’s Commendation
2003Department of Psychiatry & Human Behavior, Brown Medical School: Mentorship Award
2001Brown University: Masters of Arts (Ad Eundem)
2001Department of Psychiatry & Human Behavior, Brown Medical School: Medical Student Teaching Award
2000Rhode Island Disabled American Veterans : Physician of the Year Award
1998-1999Society for Royce Fellows, Brown University: Mentor
1998Veterans Affairs Medical Center- Providence: Special Contribution Award
1993Department of Psychiatry & Human Behavior, Brown Medical School: Research Award
1996Department of Psychiatry & Human Behavior, Brown Medical School: Research Award
 Research Expertise & Professional Interests
Dr. Kaplan serves as the Director of the Mental Health Service and Chief of Psychiatry at VA Boston Healthcare System. His clinical and pre-clinical and research focus is within the neurobiology and neuropharmacology of addiction, schizophrenia, and conditioned fear. His research specifically examines conditioned drug reward and its extinction and is published in journals of neuroscience and pharmacology.

Dr. Kaplan currently serves on the editorial board the Journal of Clinical Pharmacology. His national role in psychiatry has been recognized by the American Psychiatric Association where he was conferred as a Distinguished Fellow. He is the lead author of a text for the American Psychiatric Press Inc. for psychiatric clinicians and residents entitled Brain Circuitry and Signaling in Psychiatry which examines the functional circuitry and neurochemical pathways in psychiatric illnesses.

Dr. Kaplan is a graduate of University of Pennsylvania and Drexel University College of Medicine (Hahnemann). His residency training in Psychiatry and post-doctoral research training in Pharmacology were at Tufts University School of Medicine.

 Publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Kobrin KL, Arena DT, Heinrichs SC, Nguyen OH, Kaplan GB. Dopamine D1 receptor agonist treatment attenuates extinction of morphine conditioned place preference while increasing dendritic complexity in the nucleus accumbens core. Behav Brain Res. 2017 Mar 30; 322(Pt A):18-28. PMID: 28089852.
    View in: PubMed
  2. Kobrin KL, Moody O, Arena DT, Moore CF, Heinrichs SC, Kaplan GB. Acquisition of morphine conditioned place preference increases the dendritic complexity of nucleus accumbens core neurons. Addict Biol. 2016 Nov; 21(6):1086-1096. PMID: 26096355.
    View in: PubMed
  3. Liverant GI, Sloan DM, Pizzagalli DA, Harte CB, Kamholz BW, Rosebrock LE, Cohen AL, Fava M, Kaplan GB. Associations among smoking, anhedonia, and reward learning in depression. Behav Ther. 2014 Sep; 45(5):651-63. PMID: 25022776.
    View in: PubMed
  4. Leite-Morris KA, Kobrin KL, Guy MD, Young AJ, Heinrichs SC, Kaplan GB. Extinction of opiate reward reduces dendritic arborization and c-Fos expression in the nucleus accumbens core. Behav Brain Res. 2014 Apr 15; 263:51-9. PMID: 24406724.
    View in: PubMed
  5. Harte CB, Liverant GI, Sloan DM, Kamholz BW, Rosebrock LE, Fava M, Kaplan GB. Association between smoking and heart rate variability among individuals with depression. Ann Behav Med. 2013 Aug; 46(1):73-80. PMID: 23436273.
    View in: PubMed
  6. Heinrichs SC, Leite-Morris KA, Rasmusson AM, Kaplan GB. Repeated valproate treatment facilitates fear extinction under specific stimulus conditions. Neurosci Lett. 2013 Sep 27; 552:108-13. PMID: 23916657.
    View in: PubMed
  7. Heinrichs SC, Leite-Morris KA, Guy MD, Goldberg LR, Young AJ, Kaplan GB. Dendritic structural plasticity in the basolateral amygdala after fear conditioning and its extinction in mice. Behav Brain Res. 2013 Jul 1; 248:80-4. PMID: 23570859.
    View in: PubMed
  8. Nic Dhonnchadha BÁ, Lin A, Leite-Morris KA, Kaplan GB, Man HY, Kantak KM. Alterations in expression and phosphorylation of GluA1 receptors following cocaine-cue extinction learning. Behav Brain Res. 2013 Feb 1; 238:119-23. PMID: 23085477.
    View in: PubMed
  9. Nic Dhonnchadha BÁ, Lovascio BF, Shrestha N, Lin A, Leite-Morris KA, Man HY, Kaplan GB, Kantak KM. Changes in expression of c-Fos protein following cocaine-cue extinction learning. Behav Brain Res. 2012 Sep 1; 234(1):100-6. PMID: 22721675.
    View in: PubMed
  10. Tidey JW, Rohsenow DJ, Kaplan GB, Swift RM, Ahnallen CG. Separate and combined effects of very low nicotine cigarettes and nicotine replacement in smokers with schizophrenia and controls. Nicotine Tob Res. 2013 Jan; 15(1):121-9. PMID: 22517190.
    View in: PubMed
  11. Ahnallen CG, Liverant GI, Gregor KL, Kamholz BW, Levitt JJ, Gulliver SB, Pizzagalli DA, Koneru VK, Kaplan GB. The relationship between reward-based learning and nicotine dependence in smokers with schizophrenia. Psychiatry Res. 2012 Mar 30; 196(1):9-14. PMID: 22342123.
    View in: PubMed
  12. Kaplan GB, Leite-Morris KA, Fan W, Young AJ, Guy MD. Opiate sensitization induces FosB/?FosB expression in prefrontal cortical, striatal and amygdala brain regions. PLoS One. 2011; 6(8):e23574. PMID: 21886798.
    View in: PubMed
  13. Tidey JW, Rohsenow DJ, Kaplan GB, Swift RM, Reid N. Effects of contingency management and bupropion on cigarette smoking in smokers with schizophrenia. Psychopharmacology (Berl). 2011 Sep; 217(2):279-87. PMID: 21475970.
    View in: PubMed
  14. Kaplan GB, Moore KA. The use of cognitive enhancers in animal models of fear extinction. Pharmacol Biochem Behav. 2011 Aug; 99(2):217-28. PMID: 21256147.
    View in: PubMed
  15. Kaplan GB, Vasterling JJ, Vedak PC. Brain-derived neurotrophic factor in traumatic brain injury, post-traumatic stress disorder, and their comorbid conditions: role in pathogenesis and treatment. Behav Pharmacol. 2010 Sep; 21(5-6):427-37. PMID: 20679891.
    View in: PubMed
  16. Kaplan GB, Heinrichs SC, Carey RJ. Treatment of addiction and anxiety using extinction approaches: neural mechanisms and their treatment implications. Pharmacol Biochem Behav. 2011 Jan; 97(3):619-25. PMID: 20723558.
    View in: PubMed
  17. Sirota AD, Rohsenow DJ, Mackinnon SV, Martin RA, Eaton CA, Kaplan GB, Monti PM, Tidey JW, Swift RM. Intolerance for Smoking Abstinence Questionnaire: psychometric properties and relationship to tobacco dependence and abstinence. Addict Behav. 2010 Jul; 35(7):686-93. PMID: 20381260.
    View in: PubMed
  18. Heinrichs SC, Leite-Morris KA, Carey RJ, Kaplan GB. Baclofen enhances extinction of opiate conditioned place preference. Behav Brain Res. 2010 Mar 5; 207(2):353-9. PMID: 19840820.
    View in: PubMed
  19. Kaplan GB, Leite-Morris KA, Klufas MA, Fan W. Intra-VTA adenosine A1 receptor activation blocks morphine stimulation of motor behavior and cortical and limbic Fos immunoreactivity. Eur J Pharmacol. 2009 Jan 14; 602(2-3):268-76. PMID: 19027733.
    View in: PubMed
  20. Tidey JW, Rohsenow DJ, Kaplan GB, Swift RM, Adolfo AB. Effects of smoking abstinence, smoking cues and nicotine replacement in smokers with schizophrenia and controls. Nicotine Tob Res. 2008 Jun; 10(6):1047-56. PMID: 18584468.
    View in: PubMed
  21. Krystal JH, Gueorguieva R, Cramer J, Collins J, Rosenheck R. Naltrexone is associated with reduced drinking by alcohol dependent patients receiving antidepressants for mood and anxiety symptoms: results from VA Cooperative Study No. 425, "Naltrexone in the treatment of alcoholism". Alcohol Clin Exp Res. 2008 Jan; 32(1):85-91. PMID: 18070245.
    View in: PubMed
  22. Gelernter J, Gueorguieva R, Kranzler HR, Zhang H, Cramer J, Rosenheck R, Krystal JH. Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study. Alcohol Clin Exp Res. 2007 Apr; 31(4):555-63. PMID: 17374034.
    View in: PubMed
  23. Rohsenow DJ, Monti PM, Hutchison KE, Swift RM, MacKinnon SV, Sirota AD, Kaplan GB. High-dose transdermal nicotine and naltrexone: effects on nicotine withdrawal, urges, smoking, and effects of smoking. Exp Clin Psychopharmacol. 2007 Feb; 15(1):81-92. PMID: 17295587.
    View in: PubMed
  24. Kaplan GB, Phillips KA, Vaccaro A, Eisen JL, Posternak MA, MacAskill HS. Assessment of insight into delusional beliefs in schizophrenia using the Brown Assessment of Beliefs Scale. Schizophr Res. 2006 Feb 28; 82(2-3):279-81. PMID: 16406495.
    View in: PubMed
  25. Epstein-Lubow G, Hochstadt J, Lieberman P, Kaplan GB. Speech production in schizophrenia: preliminary data regarding voice onset time. Schizophr Res. 2006 Feb 28; 82(2-3):267-9. PMID: 16371248.
    View in: PubMed
  26. Tidey JW, Rohsenow DJ, Kaplan GB, Swift RM. Cigarette smoking topography in smokers with schizophrenia and matched non-psychiatric controls. Drug Alcohol Depend. 2005 Nov 1; 80(2):259-65. PMID: 15869844.
    View in: PubMed
  27. Tidey JW, Rohsenow DJ, Kaplan GB, Swift RM. Subjective and physiological responses to smoking cues in smokers with schizophrenia. Nicotine Tob Res. 2005 Jun; 7(3):421-9. PMID: 16085510.
    View in: PubMed
  28. Kaplan GB, McRoberts RL, Smokler HJ. Baclofen as adjunctive treatment for a patient with cocaine dependence and schizoaffective disorder. J Clin Psychopharmacol. 2004 Oct; 24(5):574-5. PMID: 15349029.
    View in: PubMed
  29. Kranzler HR, Wesson DR, Billot L. Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial. Alcohol Clin Exp Res. 2004 Jul; 28(7):1051-9. PMID: 15252291.
    View in: PubMed
  30. Turalba AV, Leite-Morris KA, Kaplan GB. Antipsychotics regulate cyclic AMP-dependent protein kinase and phosphorylated cyclic AMP response element-binding protein in striatal and cortical brain regions in mice. Neurosci Lett. 2004 Feb 26; 357(1):53-7. PMID: 15036612.
    View in: PubMed
  31. Leite-Morris KA, Fukudome EY, Shoeb MH, Kaplan GB. GABA(B) receptor activation in the ventral tegmental area inhibits the acquisition and expression of opiate-induced motor sensitization. J Pharmacol Exp Ther. 2004 Feb; 308(2):667-78. PMID: 14610238.
    View in: PubMed
  32. Kaplan GB, Leite-Morris KA, Joshi M, Shoeb MH, Carey RJ. Baclofen inhibits opiate-induced conditioned place preference and associated induction of Fos in cortical and limbic regions. Brain Res. 2003 Oct 10; 987(1):122-5. PMID: 14499954.
    View in: PubMed
  33. Cramer J, Rosenheck R, Kirk G, Krol W, Krystal J. Medication compliance feedback and monitoring in a clinical trial: predictors and outcomes. Value Health. 2003 Sep-Oct; 6(5):566-73. PMID: 14627063.
    View in: PubMed
  34. Leite-Morris KA, Fukudome EY, Kaplan GB. Opiate-induced motor stimulation is regulated by gamma-aminobutyric acid type B receptors found in the ventral tegmental area in mice. Neurosci Lett. 2002 Jan 14; 317(3):119-22. PMID: 11755254.
    View in: PubMed
  35. Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA. Naltrexone in the treatment of alcohol dependence. N Engl J Med. 2001 Dec 13; 345(24):1734-9. PMID: 11742047.
    View in: PubMed
  36. Rohsenow DJ, Monti PM, Hutchison KE, Swift RM, Colby SM, Kaplan GB. Naltrexone's effects on reactivity to alcohol cues among alcoholic men. J Abnorm Psychol. 2000 Nov; 109(4):738-42. PMID: 11195999.
    View in: PubMed
  37. Pande AC, Crockatt JG, Janney CA, Werth JL, Tsaroucha G. Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. Bipolar Disord. 2000 Sep; 2(3 Pt 2):249-55. PMID: 11249802.
    View in: PubMed
  38. Kaplan GB, Greenblatt DJ, Ehrenberg BL, Goddard JE, Harmatz JS, Shader RI. Differences in pharmacodynamics but not pharmacokinetics between subjects with panic disorder and healthy subjects after treatment with a single dose of alprazolam. J Clin Psychopharmacol. 2000 Jun; 20(3):338-46. PMID: 10831021.
    View in: PubMed
  39. Kaplan GB, Leite-Morris KA, Keith DJ. Differential effects of treatment with typical and atypical antipsychotic drugs on adenylyl cyclase and G proteins. Neurosci Lett. 1999 Oct 8; 273(3):147-50. PMID: 10515180.
    View in: PubMed
  40. Kaplan GB, Bharmal NH, Leite-Morris KA, Adams WR. Role of adenosine A1 and A2A receptors in the alcohol withdrawal syndrome. Alcohol. 1999 Oct; 19(2):157-62. PMID: 10548160.
    View in: PubMed
  41. Weisberg SP, Kaplan GB. Adenosine receptor antagonists inhibit the development of morphine sensitization in the C57BL/6 mouse. Neurosci Lett. 1999 Apr 2; 264(1-3):89-92. PMID: 10320021.
    View in: PubMed
  42. Kaplan GB, Coyle TS. Adenosine kinase inhibitors attenuate opiate withdrawal via adenosine receptor activation. Eur J Pharmacol. 1998 Nov 27; 362(1):1-8. PMID: 9865523.
    View in: PubMed
  43. Leite-Morris KA, Kaplan GB, Smith JG, Sears MT. Regulation of G proteins and adenylyl cyclase in brain regions of caffeine-tolerant and -dependent mice. Brain Res. 1998 Aug 31; 804(1):52-62. PMID: 9729274.
    View in: PubMed
  44. Kaplan GB, Sethi RK, McClelland EG, Leite-Morris KA. Regulation of G protein-mediated adenylyl cyclase in striatum and cortex of opiate-dependent and opiate withdrawing mice. Brain Res. 1998 Mar 30; 788(1-2):104-10. PMID: 9554971.
    View in: PubMed
  45. Kaplan GB, Greenblatt DJ, Ehrenberg BL, Goddard JE, Harmatz JS, Shader RI. Single-dose pharmacokinetics and pharmacodynamics of alprazolam in elderly and young subjects. J Clin Pharmacol. 1998 Jan; 38(1):14-21. PMID: 9597554.
    View in: PubMed
  46. Kaplan GB, Greenblatt DJ, Ehrenberg BL, Goddard JE, Cotreau MM, Harmatz JS, Shader RI. Dose-dependent pharmacokinetics and psychomotor effects of caffeine in humans. J Clin Pharmacol. 1997 Aug; 37(8):693-703. PMID: 9378841.
    View in: PubMed
  47. Kaplan GB, Leite-Morris KA. Up-regulation of adenosine transporter-binding sites in striatum and hypothalamus of opiate tolerant mice. Brain Res. 1997 Jul 25; 763(2):215-20. PMID: 9296562.
    View in: PubMed
  48. Kaplan GB, Sears MT. Adenosine receptor agonists attenuate and adenosine receptor antagonists exacerbate opiate withdrawal signs. Psychopharmacology (Berl). 1996 Jan; 123(1):64-70. PMID: 8741956.
    View in: PubMed
  49. Kaplan GB, Leite-Morris KA, Sears MT. Alterations of adenosine A1 receptors in morphine dependence. Brain Res. 1994 Sep 19; 657(1-2):347-50. PMID: 7820640.
    View in: PubMed
  50. Kaplan GB, Greenblatt DJ, Kent MA, Cotreau-Bibbo MM. Caffeine treatment and withdrawal in mice: relationships between dosage, concentrations, locomotor activity and A1 adenosine receptor binding. J Pharmacol Exp Ther. 1993 Sep; 266(3):1563-72. PMID: 8371158.
    View in: PubMed
  51. Kaplan GB, Cotreau MM, Greenblatt DJ. Effects of benzodiazepine administration on A1 adenosine receptor binding in-vivo and ex-vivo. J Pharm Pharmacol. 1992 Aug; 44(8):700-3. PMID: 1359103.
    View in: PubMed
  52. Kaplan GB. Neurobiological aspects of panic disorder. R I Med. 1992 May; 75(5):247-51. PMID: 1351409.
    View in: PubMed
  53. Kaplan GB, Greenblatt DJ, Kent MA, Cotreau MM, Arcelin G, Shader RI. Caffeine-induced behavioral stimulation is dose-dependent and associated with A1 adenosine receptor occupancy. Neuropsychopharmacology. 1992 May; 6(3):145-53. PMID: 1599605.
    View in: PubMed
  54. Kaplan GB, Tai NT, Greenblatt DJ, Shader RI. Caffeine-induced behavioural stimulation is dose- and concentration-dependent. Br J Pharmacol. 1990 Jul; 100(3):435-40. PMID: 2390669.
    View in: PubMed
  55. Kaplan GB, Tai NT, Greenblatt DJ, Shader RI. Separate and combined effects of caffeine and alprazolam on motor activity and benzodiazepine receptor binding in vivo. Psychopharmacology (Berl). 1990; 101(4):539-44. PMID: 2167493.
    View in: PubMed
  56. Lopez F, Miller LG, Greenblatt DJ, Kaplan GB, Shader RI. Interaction of caffeine with the GABAA receptor complex: alterations in receptor function but not ligand binding. Eur J Pharmacol. 1989 Dec 5; 172(6):453-9. PMID: 2482188.
    View in: PubMed
  57. Kaplan GB, Greenblatt DJ, Leduc BW, Thompson ML, Shader RI. Relationship of plasma and brain concentrations of caffeine and metabolites to benzodiazepine receptor binding and locomotor activity. J Pharmacol Exp Ther. 1989 Mar; 248(3):1078-83. PMID: 2539455.
    View in: PubMed
  58. Arana GW, Kaplan GB. Trazodone-induced mania following desipramine-induced mania in major depressive disorders. Am J Psychiatry. 1985 Mar; 142(3):386. PMID: 3970283.
    View in: PubMed
  59. Clark CC, Crossland J, Kaplan G, Martinez-Hernandez A. Location and identification of the collagen found in the 14.5-d rat embryo visceral yolk sac. J Cell Biol. 1982 May; 93(2):251-60. PMID: 7096438.
    View in: PubMed
Gary's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
BU Co-Authors
_
Similar BU People
_
Same Department